Tania Jain, MBBS

Tania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.

Tania Jain, MBBS, discusses the use of haploidentical donors in myelofibrosis.

Tania Jain, MBBS, discusses the unmet needs for patients with myelofibrosis who receive an allogeneic stem cell transplant.

Tania Jain, MBBS, discusses post-transplant cyclophosphamide-based transplantation from haploidentical donors in myelofibrosis.

Tania Jain, MBBS, discusses the potential for graft-versus-host disease as a complication of allogeneic stem cell transplant.

Tania Jain, MBBS, sheds light on the mutations that confer worse prognosis in myelofibrosis.

Tania Jain, MBBS, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant.

Tania Jain, MBBS, discusses the role of allogeneic stem cell transplant in myelofibrosis.

Tania Jain, MBBS, discusses the challenges with allogeneic transplant in patients with myelofibrosis.

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

You may rely too heavily on the information provided by another physician, which is (un)popularly known as “anchoring bias.”